These protective T cell antigens and epitopes will then be used to design a T cell immunotherapeutic strategy, such as the recently described Prime/Pull/Keep immunotherapy recently developed for other viral pathogens [289,290], to boost strong and long-lasting tissue-resident SARS-CoV-2-specific CD4+ and CD8+ TRM cells, that will then clear or reduce the persistent virus and vRNA reservoirs, and reverse chronic inflammatory and severe symptoms of LC. The gene discussed is CD4; the disease is laryngotracheoesophageal cleft.